<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39325643</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>615</StartPage><EndPage>625</EndPage><MedlinePgn>615-625</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciae306</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) down-regulates angiotensin-converting enzyme 2, potentially increasing angiotensin II. We hypothesized that losartan compared to usual care decreases mortality and is safe in patients hospitalized with coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of losartan versus usual care on 28-day mortality in patients hospitalized for acute COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eligibility criteria included adults admitted for acute COVID-19. Exclusion criteria were hypotension, hyperkalemia, acute kidney injury, and use of angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors within 7 days. Participants were randomized to losartan 25-100 mg/day orally for the hospital duration or 3 months or the control arm (usual care) in 29 hospitals in Canada and France. The primary outcome was 28-day mortality. Secondary outcomes were hospital mortality, organ support, and serious adverse events (SAEs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The trial was stopped early because of a serious safety concern with losartan. In 341 patients, any SAE and hypotension were significantly higher in the losartan versus usual care groups (any SAE: 39.8% vs 27.2%, respectively, P = .01; hypotension: 30.4% vs 15.3%, respectively, P &lt; .001) in both ward and intensive care patients. The 28-day mortality did not differ between losartan (6.5%) versus usual care (5.9%) (odds ratio, 1.11 [95% confidence interval, .47-2.64]; P = .81), nor did organ dysfunction or secondary outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Caution is needed in deciding which patients to start or continue using ARBs in patients hospitalized with pneumonia to mitigate risk of hypotension, acute kidney injury, and other side effects. ARBs should not be added to care of patients hospitalized for acute COVID-19.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT04606563.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Karen C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asfar</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McGill's Interdisciplinary Initiative in Infection and Immunity, Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demiselle</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Terry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walley</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haljan</LastName><ForeName>Greg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geri</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris Ambroise Paré, Boulogne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auchabie</LastName><ForeName>Johann</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Service de Réanimation Polyvalente, Centre Hospitalier de Cholet.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quenot</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire Dijon, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Todd C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>McGill's Interdisciplinary Initiative in Infection and Immunity, McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Niagara Health, McMaster University, St Catherines, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meziani</LastName><ForeName>Ferhat</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamontagne</LastName><ForeName>Francois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Sherbrooke, University of Sherbrooke, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubee</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Service de Maladies Infectieuses, Centre Hospitalier Universitaire d'Angers, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasocki</LastName><ForeName>Sigismond</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire Angers, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovakim</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Royal Jubilee Hospital, Island Health, Victoria, British Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Royal Jubilee Hospital, Island Health, Victoria, British Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turgeon</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris Avicenne, Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebas</LastName><ForeName>Eddy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service de Réanimation Polyvalente, Centre Hospitalier Bretagne-Atlantique, Vannes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goudelin</LastName><ForeName>Marine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Nanaimo Regional General Hospital, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teale</LastName><ForeName>Alastair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Nanaimo Regional General Hospital, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mira</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris, Cochin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daneman</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adhikari</LastName><ForeName>Neill K J</ForeName><Initials>NKJ</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gousseff</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne-Maladies Infectieuses-Hématologie, Centre Hospitalier Bretagne-Atlantique, Vannes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroy</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service de médecine polyvalente et maladies infectieuses, Centre Hospitalier Melun, Melun, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plantefeve</LastName><ForeName>Gaetan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de Réanimation Polyvalente, Centre Hospitalier Argenteuil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rispal</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Service de médecine interne, Centre Hospitalier Agen, Agen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Courtois</LastName><ForeName>Roxane</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Service de Médecine post-urgences-Maladies infectieuses, Centre Hospitalier de Cholet, Cholet, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winston</LastName><ForeName>Brent</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departments of Critical Care Medicine, Medicine, and Biochemistry and Molecular Biology, Foothills Medical Centre, University of Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Simon Fraser University, Surrey, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birks</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Critical Care Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Simon Fraser University, Surrey, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bienvenu</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de médecine interne, Hôpital St Joseph, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tadie</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation et de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talarmin</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Service de médecine interne, maladies du sang et infectiologie, Centre Hospitalier de Quimper, Quimper, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansart</LastName><ForeName>Severine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Maladies Infectieuses, Centre Hospitalier Régional Universitaire Brest, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ARBs CORONA II Team
</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04606563</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JMS50MPO89</RegistryNumber><NameOfSubstance UI="D019808">Losartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019808" MajorTopicYN="Y">Losartan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007022" MajorTopicYN="N">Hypotension</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047228" MajorTopicYN="N">Angiotensin II Type 1 Receptor Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">angiotensin receptor blocker</Keyword><Keyword MajorTopicYN="N">losartan</Keyword><Keyword MajorTopicYN="N">mortality</Keyword></KeywordList><CoiStatement>Potential conflicts of interest . J. A. R. reports patents owned by the University of British Columbia that are related to (i) the use of PCSK9 inhibitor(s) in sepsis, (ii) the use of vasopressin in septic shock, and (iii) a patent owned by Ferring for use of selepressin in septic shock; J. A. R. is an inventor on these patents. J. A. R. was a founder, director, and shareholder in Cyon Therapeutics Inc (now closed) and is a shareholder in Molecular You Corp; is the Senior Research Advisor of the British Columbia, Canada Post COVID–Interdisciplinary Clinical Care Network (PC-ICCN); reports receiving consulting fees in the last 3 years as a funded member of the data and safety monitoring board of a National Institutes of Health–sponsored trial of plasma in COVID-19 (PASS-IT-ON; 2020–2021); has received grants for COVID-19 and for pneumonia research from CIHR and the St Paul's Foundation; and was a nonfunded science advisor and member of the government of Canada COVID-19 Therapeutics Task Force (June 2020–2021). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asfar</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demiselle</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mann</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohoe</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leung</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyd</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walley</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sweet</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haljan</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharif</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ovakim</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forrest</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teale</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birk</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winston</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fowler</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dameman</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adhikari</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsang</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamontagne</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turgeon-Fournier</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asfar</LastName></Investigator><Investigator ValidYN="Y"><LastName>Demiselle</LastName></Investigator><Investigator ValidYN="Y"><LastName>Geri</LastName><ForeName>D G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auchabie</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quenot</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meziani</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubee</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lasocki</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebas</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goudelin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mira</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gousseff</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leroy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plantefev</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rispal</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Courtois</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bievenue</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tadie</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talarmin</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ansart</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yi</LastName><ForeName>Tae Won</ForeName><Initials>TW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Adeera</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325643</ArticleId><ArticleId IdType="pmc">PMC11426262</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae306</ArticleId><ArticleId IdType="pii">7706430</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. . Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384:693–704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al. . Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 2021; 385:790–802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397:1637–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, et al. . Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021; 384:795–807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, et al. . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181:271–80.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yang Y, Zhang C, et al. . Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088566</ArticleId><ArticleId IdType="pubmed">32048163</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Kuba K, Rao S, et al. . Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436:112–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094998</ArticleId><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 2021; 51:1107–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7124128</ArticleId><ArticleId IdType="pubmed">32246317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82–97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870827</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Elia JA, Bayliss G, Gleason RE, Weinrauch LA. Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review. Clin Kidney J 2016; 9:705–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036907</ArticleId><ArticleId IdType="pubmed">27679717</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh KK, Chung WJ, Ahn JY, et al. . Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2004; 177:155–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488878</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; 382:1653–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121452</ArticleId><ArticleId IdType="pubmed">32227760</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, Gu H, Zhao Z, et al. . Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 2014; 4:7027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229671</ArticleId><ArticleId IdType="pubmed">25391767</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte M, Pelorosso F, Nicolosi LN, et al. . Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine 2021; 37:100962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8225700</ArticleId><ArticleId IdType="pubmed">34189447</ArticleId></ArticleIdList></Reference><Reference><Citation>Geriak M, Haddad F, Kullar R, et al. . Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia. Infect Dis Ther 2021; 10:1323–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112834</ArticleId><ArticleId IdType="pubmed">33977506</ArticleId></ArticleIdList></Reference><Reference><Citation>Nouri-Vaskeh M, Kalami N, Zand R, et al. . Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial. Int J Clin Pract 2021; 75:e14124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7995089</ArticleId><ArticleId IdType="pubmed">33650197</ArticleId></ArticleIdList></Reference><Reference><Citation>Puskarich MA, Ingraham NE, Merck LH, et al. . Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial. JAMA Netw Open 2022; 5:e222735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8928006</ArticleId><ArticleId IdType="pubmed">35294537</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer A, Schreinlechner M, Sappler N, et al. . Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med 2021; 9:863–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195495</ArticleId><ArticleId IdType="pubmed">34126053</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JB, Hanff TC, William P, et al. . Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med 2021; 9:275–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832152</ArticleId><ArticleId IdType="pubmed">33422263</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes RD, Macedo AVS, de Barros E Silva PGM, et al. . Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA 2021; 325:254–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816106</ArticleId><ArticleId IdType="pubmed">33464336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnanenthiran SR, Borghi C, Burger D, et al. . Renin-angiotensin system inhibitors in patients with COVID-19: a meta-analysis of randomized controlled trials led by the International Society of Hypertension. J Am Heart Assoc 2022; 11:e026143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9496439</ArticleId><ArticleId IdType="pubmed">36000426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Cau A, Cheng MP, et al. . Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors in COVID-19: meta-analysis/meta-regression adjusted for confounding factors. CJC Open 2021; 3:965–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023793</ArticleId><ArticleId IdType="pubmed">33842874</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocheleau GLY, Lee T, Mohammed Y, et al. . Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19. Crit Care Med 2022; 50:1306–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380153</ArticleId><ArticleId IdType="pubmed">35607951</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight SR, Ho A, Pius R, et al. . Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ 2020; 370:m3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116472</ArticleId><ArticleId IdType="pubmed">32907855</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stefano L, Ram M, Scharfstein DO, et al. . Losartan in hospitalized patients with COVID-19 in North America: an individual participant data meta-analysis. Medicine (Baltimore) 2023; 102:e33904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10256351</ArticleId><ArticleId IdType="pubmed">37335665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MMY, Kondo T, Campbell RT, et al. . Effects of renin-angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2024; 10:68–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10766905</ArticleId><ArticleId IdType="pubmed">37740450</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the R-CAP Investigators; Lawler PR, Derde LPG, van de Veerdonk FL, et al. . Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19: a randomized clinical trial. JAMA 2023; 329:1183–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10326520</ArticleId><ArticleId IdType="pubmed">37039790</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen ME, Yun J, Griggs JM, Jackson EA, Richardson CR. Anti-hypertensive medication combinations in the United States. J Am Board Fam Med 2020; 33:143–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31907256</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy DP, Drawz PE, Foley RN. Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States. J Am Soc Nephrol 2019; 30:1314–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622408</ArticleId><ArticleId IdType="pubmed">31167823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim SL, Jiroutek MR, Holland MA, Sutton BS. Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: analysis from the National Ambulatory Medical Care Survey. Prev Med Rep 2016; 3:166–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4929215</ArticleId><ArticleId IdType="pubmed">27419010</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran RH, Aldemerdash A, Chang P, et al. . Guideline-directed medical therapy and survival following hospitalization in patients with heart failure. Pharmacotherapy 2018; 38:406–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902433</ArticleId><ArticleId IdType="pubmed">29423950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Cheng MP, Vinh DC, et al. . Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. CMAJ Open 2022; 10:E379–89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9022939</ArticleId><ArticleId IdType="pubmed">35440485</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Gheblawi M, Nikhanj A, et al. . Dysregulation of ACE (angiotensin-converting enzyme)-2 and renin-angiotensin peptides in SARS-CoV-2 mediated mortality and end-organ injuries. Hypertension 2022; 79:365–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">34844421</ArticleId></ArticleIdList></Reference><Reference><Citation>Files DC, Gibbs KW, Schaich CL, et al. . A pilot study to assess the circulating renin-angiotensin system in COVID-19 acute respiratory failure. Am J Physiol Lung Cell Mol Physiol 2021; 321:L213–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270515</ArticleId><ArticleId IdType="pubmed">34009036</ArticleId></ArticleIdList></Reference><Reference><Citation>Montiel V, Lobysheva I, Gérard L, et al. . Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine 2022; 77:103893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8865837</ArticleId><ArticleId IdType="pubmed">35219085</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominiczak A, Mancia G. Joint editorial for the International Society of Hypertension guidelines. Hypertension 2020; 75:1419.</Citation><ArticleIdList><ArticleId IdType="pubmed">32370573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>